Ortivus AB ser. A
The answer first
Does Ortivus beat the market?
No, Ortivus has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 2% of Nordic stocks
- Quality20
- Value15
- Trend8
No. 188 of 195 in healthcare
Max for seven days
Follow Ortivus with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Ortivus
Your first answer is free, no account needed.
Do you own Ortivus, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Ortivus and a few more. Free, no card.
Super Stock+44.6%In short
- Ortivus has fallen 48.6% over the past year, including dividends.
- Overall, Ortivus ranks better than 2% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 82.9%. The price is 98.8% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 2% of Nordic stocks.
No. 188 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 172 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity1.42
- Asset turnoverSales divided by everything the company owns1.03
- Return on equityProfit divided by equity−100.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 115 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity6.3
- P/SPrice divided by sales1.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 159 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−43.6%
- 6 months−33.5%
- 9 months−56.2%
- 12 months−48.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Ortivus
Ortivus AB ser. A is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 32 employees.
Ortivus AB (publ) develops and commercializes medical technology solutions and e-health for healthcare industry in Sweden and internationally. The company offers MobiMed Monitor that monitor and shares vital signs and ECG; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed enRoute, a navigation, case management, and mass casualty management; MobiMed FleetCtrl, a a software application that regular controls, checklists, and documentation tailored for seamless fleet management; MobiMed Life, a heart safe solution. It also provides emergency medical services, primary care, and rescue services.


See the full analysis of Ortivus.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card